StockData
Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc. (TMCI) stock

TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.44+0.02 (+0.45%)

Close on Nov 17, 2026Market cap $288.75MP/E –Yield –

Earnings

Treace Medical Concepts's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 26, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$48.30M
-3.8% on a year earlier
Adjusted EPS, Q3 FY2026
-$0.19
-$0.26 a year earlier
Latest guidance
Lowered
Nov 6, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Treace Medical Concepts's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 26, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 6, 2026before the open$48.30M-3.8%-$0.19–Release
Q2 FY2026ended Jun 30, 2026Aug 7, 2026before the open$45.40M-4.2%-$0.24–Release
Q1 FY2026ended Mar 31, 2026May 8, 2026before the open$47.20M-10.3%-$0.28–Release
Q4 FY2025ended Dec 31, 2025Feb 27, 2026before the open$62.50M-9.0%-$0.15–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$50.20M+11.3%-$0.26–Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$47.40M+6.5%-$0.28–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$52.60M+2.9%-$0.25–Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$68.70M+10.5%-$0.01–Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024after the close$45.10M+10.5%-$0.25–Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$44.50M+6.0%-$0.34–Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$51.10M+21.1%-$0.30–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Treace Medical Concepts's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
declineFY2026-4% – 0%–NewAug 7, 2026
revenueGAAPFY2026$206.00M – $210.00M$202.00M – $212.00MNarrowedNov 6, 2026
revenueFY2026$200.00M – $212.00M–NewFeb 27, 2026
revenue guidanceFY2026$204.00M – $212.00M–NewAug 7, 2026
loss in Adjusted EBITDAnon-GAAPFY2026$1.00M – $2.00M$4.00M – $6.00MLoweredNov 6, 2026
loss in Adjusted EBITDAnon-GAAPFY2026-$5.00M – -$3.00M–NewAug 7, 2026
reduction in cash usageFY2026+50%+50%ReaffirmedNov 6, 2026
reduction in cash usageFY202650%–NewAug 7, 2026
reduction in cash usageFY202650%–NewMay 8, 2026

Guidance vs results

The last range Treace Medical Concepts gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$211.00M – $213.00M$212.70MΣ4QWithin range
FY2025Revenue growth+1% – +2%+1.58%Σ4QWithin range

Guidance history

Every forecast Treace Medical Concepts put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 6, 2026loss in Adjusted EBITDAFY2026$1.00M – $2.00MLowered
Nov 6, 2026reduction in cash usageFY2026+50%Reaffirmed
Nov 6, 2026revenueFY2026$206.00M – $210.00MNarrowed
Aug 7, 2026loss in Adjusted EBITDAFY2026-$5.00M – -$3.00MNew
Aug 7, 2026reduction in cash usageFY202650%New
Aug 7, 2026declineFY2026-4% – 0%New
Aug 7, 2026revenue guidanceFY2026$204.00M – $212.00MNew
May 8, 2026loss in Adjusted EBITDAFY2026$4.00M – $6.00MReaffirmed
May 8, 2026reduction in cash usageFY202650%New
May 8, 2026revenue guidanceFY2026$202.00M – $212.00MNew
Feb 27, 2026Adjusted EBITDAFY2026$4.00M – $6.00MNew
Feb 27, 2026reduction in cash usageFY2026+50%New
Feb 27, 2026revenueFY2026$200.00M – $212.00MNew
Nov 6, 2025Adjusted EBITDA improvementFY2025+32% – +41%New
Nov 6, 2025loss in Adjusted EBITDAFY2025$6.50M – $7.50MNew
Nov 6, 2025reduction in cash usedFY202543% – 47%New
Nov 6, 2025revenue growthFY2025+1% – +2%New
Nov 6, 2025revenueFY2025$211.00M – $213.00MNew
Aug 7, 2025growthFY2025+7% – +10%Reaffirmed
Aug 7, 2025revenue guidanceFY2025$224.00M – $230.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Treace Medical Concepts filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?